Susquehanna Portfolio Strategies, LLC
Position in NTLA — Intellia Therapeutics, Inc.
CIK 1996449
Bala Cynwyd, PA
Position in NTLA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,460,249
+$267,753 QoQ
Shares Held
113,904
-14.1% QoQ
Ownership
0.082%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Susquehanna Portfolio Strategies, LLC holds $315,293,732 across 114 Biotechnology names. NTLA ranks #53 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
207,527 | $33,934,815 | |
| 2 | MRNA |
Moderna, Inc.
|
471,043 | $23,928,984 | |
| 3 | CYTK |
Cytokinetics Inc
|
278,429 | $18,351,255 | |
| 4 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,075,323 | $15,549,170 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
29,189 | $13,034,056 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
188,100 | $12,156,903 | |
| 7 | COGT |
Cogent Biosciences, Inc.
|
229,755 | $8,843,269 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
43,277 | $8,181,516 |
All Filings in NTLA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,460,249 | 113,904 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,192,496 | 132,647 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,290,813 | 132,647 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,244,228 | 132,647 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $165,712 | 23,307 | Shares | Sole | 2025-05-14 | |
| No filing history on record for this holder in this stock. | ||||||